- Home
- CIFR vs RXST Comparison
CIFR vs RXST Comparison
Compare CIFR & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- RXST
- Stock Information
- Founded
- CIFR 2021
- RXST 1997
- Country
- CIFR United States
- RXST United States
- Employees
- CIFR N/A
- RXST N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- RXST Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CIFR Finance
- RXST Health Care
- Exchange
- CIFR Nasdaq
- RXST Nasdaq
- Market Cap
- CIFR 882.1M
- RXST 1.0B
- IPO Year
- CIFR N/A
- RXST 2021
- Fundamental
- Price
- CIFR $3.12
- RXST $15.29
- Analyst Decision
- CIFR Strong Buy
- RXST Buy
- Analyst Count
- CIFR 10
- RXST 10
- Target Price
- CIFR $8.03
- RXST $39.30
- AVG Volume (30 Days)
- CIFR 20.8M
- RXST 1.1M
- Earning Date
- CIFR 05-06-2025
- RXST 05-07-2025
- Dividend Yield
- CIFR N/A
- RXST N/A
- EPS Growth
- CIFR N/A
- RXST N/A
- EPS
- CIFR N/A
- RXST N/A
- Revenue
- CIFR $152,092,000.00
- RXST $148,310,000.00
- Revenue This Year
- CIFR $90.57
- RXST $22.25
- Revenue Next Year
- CIFR $78.51
- RXST $18.58
- P/E Ratio
- CIFR N/A
- RXST N/A
- Revenue Growth
- CIFR N/A
- RXST 46.70
- 52 Week Low
- CIFR $1.86
- RXST $12.53
- 52 Week High
- CIFR $7.99
- RXST $61.10
- Technical
- Relative Strength Index (RSI)
- CIFR 46.63
- RXST 47.18
- Support Level
- CIFR $3.34
- RXST $15.66
- Resistance Level
- CIFR $3.65
- RXST $16.48
- Average True Range (ATR)
- CIFR 0.27
- RXST 0.89
- MACD
- CIFR -0.04
- RXST 0.36
- Stochastic Oscillator
- CIFR 11.24
- RXST 65.56
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.